BPH Global Valuation

Is BP8 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BP8 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate BP8's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate BP8's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BP8?

Key metric: As BP8 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for BP8. This is calculated by dividing BP8's market cap by their current revenue.
What is BP8's PS Ratio?
PS Ratio	10.8x
Sales	AU$109.97k
Market Cap	AU$1.19m

BP8 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	11.8x
Enterprise Value/EBITDA	-0.8x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does BP8's PS Ratio compare to its peers?

The above table shows the PS ratio for BP8 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	13.1x
RGS Regeneus	4x	n/a	AU$1.5m
HXL Hexima	35.2x	n/a	AU$2.2m
NC6 Nanollose	9.6x	n/a	AU$2.9m
VBS Vectus Biosystems	3.7x	n/a	AU$4.3m
BP8 BPH Global	10.8x	n/a	AU$1.2m

Price-To-Sales vs Peers: BP8 is good value based on its Price-To-Sales Ratio (10.8x) compared to the peer average (13.1x).

Price to Sales Ratio vs Industry

How does BP8's PS Ratio compare vs other companies in the AU Biotechs Industry?

8 Companies	Price / Sales	Estimated Growth	Market Cap
ARX Aroa Biosurgery	3.6x	20.1%	US$146.81m
IMC Immuron	3.5x	59.7%	US$11.17m
ATH Alterity Therapeutics	4x	25.0%	US$10.37m
BNO Bionomics	2.4x	-5.3%	US$9.52m

8 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: BP8 is expensive based on its Price-To-Sales Ratio (10.8x) compared to the Australian Biotechs industry average (10x).

Price to Sales Ratio vs Fair Ratio

What is BP8's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BP8 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	10.8x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate BP8's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Neuren Pharmaceuticals

AU$1.6b

A biopharmaceutical company, develops drugs for the treatment of neurological disorders.

NEU

AU$12.36

-26.0%

-17.0%

AVITA Medical

US$349.9m

Operates as a regenerative medicine company in the United States and internationally.

AVH

US$3.93

2.3%

20.4%

Medical Developments International

AU$47.3m

Manufactures and distributes emergency medical solutions in Australia, Europe, the United States, and internationally.

MVP

AU$0.42

-5.6%

-46.8%